There will soon be two gene therapies available for patients with haemophilia B in the EU after the European Commission approved Pfizer's fidanacogene elaparvovec under the Durveqtix brand
After a couple of days filled with investor nervousness, Arcutis Biotherapeutics has claimed FDA approval of Zoryve for the new indication of atopic dermatitis (AD), a common form of eczema
Roche’s Genentech unit has said will reintroduce its Susvimo implant for eyesight-robbing disease age-related macular degeneration (AMD), which was withdrawn from sale in 2022 due to manufa
Chronic obstructive pulmonary disease (COPD) has seen no new therapies brought to market for around 10 years – and now there have been two in the space of a couple of weeks.
Eli Lilly finally has FDA approval for its amyloid-busting Alzheimer’s disease therapy donanemab and will launch it at a cost it claims could deliver savings compared to a rival therapy fro
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh